Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 2/3 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Recurrence 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × glumetinib × Clear all
NCT06525350 2024-07-29

A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel(Albumin Bound)Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2 Not yet recruiting
256 enrolled

Recurrence

NCT06452433 2024-06-11

Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
91 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡